Manufacturer 340B
Contract Pharmacy Actions
Since 2020, drug manufacturers have implemented policies restricting the purchase of 340B-priced drugs for Covered Entities when dispensing through Contract Pharmacies.
Select a year below to get the latest manufacturer updates and details.
2020
2022
Bausch Health
Aug 1, 2022
340B > ESP: Data Required
Products Included: All products
Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via
340B ESP.
Exelixis
July 6, 2022
340B > ESP: Data Required
Products Included: Cometriq, Cabometyx
Effective July 6th, 2022, Exelixis will only provide 340B pricing on COMETRIQ and CABOMETYX to a single Contract Pharmacy within the specialty pharmacy network if the Covered Entity does not have an
in-house pharmacy location. Federal Grantees not subject to limitations.
J&J
May 2, 2022
340B > ESP: Data Required
Products Included: Twenty-nine (29) products listed in notice
Effective May 2nd, 2022, Janssen will only provide a 340B price on products listed in their “Bill To/Ship To Policy” to a single Contract Pharmacy if the non-grantee does not have an in-house pharmacy location. Federal Grantees not subject to limitations.
Gilead
May 2, 2022
340B > ESP: Data Required
Products Included: Epclusa, Harvoni, Sovaldi
and Vosevi
Effective May 2nd, 2022, Gilead will only provide a 340B price on branded hepatitis C products to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location.
GSK
April 1, 2022
340B > ESP: Data Required
Products Included: Nine (9) respiratory products, including Advair
Effective April 1st, 2022, GSK will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.
Pfizer
Mar 1, 2022
340B > ESP: Data Required
Products Included: Xeljanz, eleven (11) oral
oncology products
Effective March 1st, 2022, Pfizer will recognize up to two designated contract pharmacy locations per 340B hospital that lacks a wholly owned: one for Xeljanz and a second for oral oncology products. Multiple Contract Pharmacy access is permissible through provision of claims data via 340B ESP.
Bristol Myers Squibb
Mar 1, 2022
340B > ESP: No Data Option
Products Included: All products
Effective March 1st, 2022, BMS will recognize up to
two designated 340B contract pharmacy locations
per 340B hospital that lacks an entity-owned
pharmacy: one for IMiDs and a second for non-IMiDs. Federal Grantees not subject to limitations on
non-IMiD products.
Abbvie
Feb 1, 2022
340B > ESP: Data Required
Products Included: Aimovig, Enbrel, Otezia, Repatha
Effective February 1st, 2022, AbbVie will only provide 340B priced product to a single Contract Pharmacy if Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
Amgen
Jan 3, 2022
340B > ESP: Data Required
Products Included: Aimovig, Enbrel, Otezia, Repatha
Effective January 3rd, 2022, Amgen will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Policy is limited to four drugs and doesn’t include Federal Grantees.
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
Read the fulL PDF >
2021
Eli Lilly
September 1, 2020
340B > ESP: Data Required
Products Included: All Products
Read the fulL PDF >
Effective September 1st, 2020, Lilly will restrict access for 340B priced product to Contract Pharmacies,
except insulin.
Sanofi
October 1, 2020
340B > ESP: Data Required
Products Included: All Products
Read the fulL PDF >
Effective October 1st, 2020, Sanofi will only provide 340B priced product to a Contract Pharmacy if
Covered Entity provides Claims Level Detail via 340B ESP platform.
AstraZeneca
October 1, 2020
340B > ESP: No Data Option
Products Included: All Products
Read the fulL PDF >
Effective October 1st, 2020, AstraZeneca will
only provide 340B priced product to a single
Contract Pharmacy.
Novartis
November 16, 2020
340B > ESP: Voluntary Data Sharing
Products Included: All Products
Read the fulL PDF >
Effective November 16th, 2020, Novartis will restrict 340B priced product to Contract Pharmacies based on a 40 mile radius for hospital Covered Entities. Federal Grantees not subject to limitations.
United Therapeutics
November 20, 2020
340B > ESP: Data Required
Products Included: Adcirca, licensed with Lilly
Read the fulL PDF >
Effective December 1st, 2021, United Therapeutics will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform.
Novo Nordisk
Jan 1, 2021
340B > ESP: No Data Option
Products Included: All Products
Read the fulL PDF >
Effective January 1st, 2021, Novo Nordisk will restrict 340B priced product to Contract Pharmacies for hospital Covered Entities. Federal Grantees not subject to limitation.
Boehringer Ingelheim
Aug 1, 2021
340B > ESP: No Data Option
Products Included: All Products
Read the fulL PDF >
Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions
from August 1st, 2021, remain effective. Link to both notices below.
Merck
Sep 1, 2021
340B > ESP: Data Required
Products Included: All Products
Read the fulL PDF >
Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
UCB Pharma
Dec 13, 2021
340B > ESP: No Data Option
Products Included: Eight (8) product families
Read the fulL PDF >
Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.
2020
Back to top
2023
Novo Nordisk
Jan 1, 2023
340B > ESP: Data Required
Products Included: All Products
Read the fulL PDF >
On December 2nd, 2022, Novo Nordisk announced an expansion to their Contract Pharmacy policy allowing 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform for dispenses on or after January 1st, 2023.
Biogen
Feb 1, 2023
340B > ESP: Data Required
Products Included: Avonex and Plegridy
Read the fulL PDF >
Effective March 7th, 2023, Janssen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. An additional specialty pharmacy part of limited distribution system may be designated. Federal Grantees not subject to limitations.
2022
2023
2021
Back to top
Biogen
Feb 1, 2023
340B > ESP: Data Required
Products Included: Avonex and Plegridy
Read the fulL PDF >
Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if the Covered Entity does not have an
in-house pharmacy. Policy is limited to two drugs and doesn’t include Federal Grantees.
EMD SERONO
March 1, 2023
340B > ESP: No Data Option
Products Included: Rebif and Gonal-F
Read the fulL PDF >
Effective March 1, 2023, EMD Serono (EMDS) will
only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an in-house pharmacy location.
Grantees not subject to limitations.
JANSSEN
March 7, 2023
340B > ESP: Data Required
Products Included: Thirty (30) products listed in notice
Read the fulL PDF >
Effective March 7th, 2023, Janssen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the
non-grantee doesn’t have an in-house pharmacy.
An additional specialty pharmacy part of limited distribution system may be designated. Federal Grantees not subject to limitations.
BAYER
March 1, 2023
340B > ESP: Data Option
Products Included: Twelve (12) products listed in notice
Read the fulL PDF >
Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.
Janssen
March 7, 2023
340B > ESP: Data Required
Products Included: Thirty (30) products listed in notice
Read the fulL PDF >
Effective March 7th, 2023, Janssen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. An additional specialty pharmacy part of limited distribution system may be designated. Federal Grantees not subject to limitations.
EMD SERONO
March 1, 2023
340B > ESP: No Data Option
Products Included: Rebif and Gonal-F
Read the fulL PDF >
Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if
the Covered Entity does not have an
in-house pharmacy. Policy is limited
to two drugs and doesn’t include Federal Grantees.
Bayer
March 1, 2023
340B > ESP: Data Option
Products Included: Twelve (12) products listed in notice
Read the fulL PDF >
Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if
the Covered Entity does not have an
in-house pharmacy. Policy is limited
to two drugs and doesn’t include Federal Grantees.
Amgen
April 11, 2023
340B > ESP: Data Required
Products Included: Six (6) products listed in notice
Read the fulL PDF >
Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.
Abbvie
April 17, 2023
340B > ESP: Data Required
Products Included: Listed in notice
Read the fulL PDF >
Effective April 17, 2023, AbbVie will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations. *Updated policy now includes 90 drugs from original 25 added to exclusion list.
Pfizer
May 1, 2023
340B > ESP: No Data Option
Products Included: Xeljanz
Read the fulL PDF >
Effective May 1, 2023, Pfizer will only provide Xeljanz at a 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.
GSK
May 1, 2023
340B > ESP: No Data Option
Products Included: All products
Read the fulL PDF >
Effective April 1st, 2022, GSK will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.
Novartis
May 1, 2023
340B > ESP: No Data Option
Products Included: All products
Read the fulL PDF >
Effective May 1, 2023, Novartis will only provide 340B priced product to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.
Amgen
April 11, 2023
340B > ESP: Data Required
Products Included: Six (6) products listed in notice
Read the fulL PDF >
Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.
Abbvie
April 17, 2023
340B > ESP: Data Required
Products Included: Listed in notice
Read the fulL PDF >
Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if
the Covered Entity does not have an
in-house pharmacy. Policy is limited
to two drugs and doesn’t include Federal Grantees.
Pfizer
May 1, 2023
340B > ESP: No Data Option
Products Included: Xeljanz
Read the fulL PDF >
Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.
GSK
May 1, 2023
340B > ESP: No Data Option
Products Included: All products
Read the fulL PDF >
Effective March 1, 2023, EMD Serono (EMDS) will only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an
in-house pharmacy location. Grantees not subject to limitations.
Novartis
May 1, 2023
340B > ESP: No Data Option
Products Included: All products
Read the fulL PDF >
Effective May 1, 2023, Novartis will only provide 340B priced product to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.